

Mark D. Kaufmann, MD, FAAD President
Terrence A. Cronin Jr., MD, FAAD President-elect
Linda F. Stein Gold, MD, FAAD Vice President
Robert S. Kirsner, MD, PhD, FAAD Vice President-elect
Daniel D. Bennett, MD, FAAD Secretary-Treasurer
Keyvan Nouri, MD, MBA, FAAD Assistant Secretary-Treasurer
Elizabeth K. Usher, MBA Executive Director & CEO

February 21, 2023

The Honorable Melony Ghee Griffith Chair, Senate Finance Committee 11 Bladen Street James Senate Office Building, Room 220 Annapolis, Maryland 21401

## **Re: Support for Senate Bill 515**

Dear Chair Griffith,

On behalf of the nearly 16,500 U.S. physician members of the American Academy of Dermatology Association, we are writing to share our support for Senate Bill 515. This legislation would be a critical step to ensure patients have access to their prescription medicines. Pursuant to Senate Bill 515, health insurers would be required to expeditiously grant a step therapy override determination request if, in the professional judgment of the prescribing physician, the step therapy requirement would be medically inappropriate for that patient. We urge members of the Senate Finance Committee to support Senate Bill 515.

Step therapy protocols, a cost containment tool used by health insurance plans, require patients to try one or more prescription drugs before coverage is provided for a drug selected by the patient's health care provider. We understand the need to contain health care costs, but we are concerned that step therapy strategies for medication and other treatment selection have the potential to impact patient outcomes and quality of life.

Requiring patients to try and fail treatments jeopardizes the health of patients, potentially resulting in dangerous consequences. In some instances, health plans force patients to return to the same treatments that have proven to be ineffective when tried previously under a different health plan. The decision to change plans may occur through no fault of the patients but rather an employer's decision to change plans.

EMAIL: mrc@aad.org WEB: aad.org MAIN: (847) 330-0230 FAX: (847) 240-1859 MAIN: (202) 842-3555 FAX: (202) 842-4355 Support Senate Bill 515 February 21, 2023 Page 2 of 2

Further, step therapy interferes with the patient-physician relationship by preventing dermatologists from prescribing drugs they know will provide the best treatment results in the most effective manner. Senate Bill 515 would ensure that step therapy protocols used by health plans in Maryland will preserve the heath care provider's right to make treatment decisions in the best interest of the patient. Physicians know their patients' medical history, which enables them to identify potential contraindications and life-threatening adverse reactions. Retaining physicians' medical judgement in patients' treatment plans is a cost-effective way to prevent health care dollars from being used on medications that are not effective. It also prevents patients from enduring a prolonged course of treatment that includes scheduling multiple visits to their physician and spending money on prescription medications that are not effective.

We appreciate the opportunity to provide written comments on this important public health issue and urge your support for Senate Bill 515. As physicians, our number one priority is the health and welfare of our patients. The enactment of this legislation will improve access to prescription medications that are in the best interest of the patient. For further information, please contact Lisa Albany, director, state policy for the American Academy of Dermatology Association, at <a href="mailto:lalbany@aad.org">lalbany@aad.org</a> or (202) 286-1041.

Sincerely,

Mark D. Kaufmann, MD, FAAD

President

American Academy of Dermatology Association